NF-kappa B Activation Is a Critical Regulator of Human Granulocyte Apoptosis in Vitro*

Carol WardDagger , Edwin R. Chilvers§, Mark F. Lawson, James G. Pryde, Satoko Fujihara, Stuart N. Farrow, Christopher Haslett, and Adriano G. Rossiparallel

From the Respiratory Medicine Unit, Department of Medicine (RIE), Rayne Laboratory, University of Edinburgh Medical School, Teviot Place, Edinburgh, EH8 9AG, United Kingdom and  The Cell Biology Unit, Glaxo-Wellcome, Gunnelswood Road, Stevenage, Herts, SG1 2NY, United Kingdom

    ABSTRACT
Top
Abstract
Introduction
References

During beneficial inflammation, potentially tissue-damaging granulocytes undergo apoptosis before being cleared by phagocytes in a non-phlogistic manner. Here we show that the rate of constitutive apoptosis in human neutrophils and eosinophils is greatly accelerated in both a rapid and concentration-dependent manner by the fungal metabolite gliotoxin, but not by its inactive analog methylthiogliotoxin. This induction of apoptosis was abolished by the caspase inhibitor zVAD-fmk, correlated with the inhibition of nuclear factor-kappa B (NF-kappa B), and was mimicked by a cell permeable inhibitory peptide of NF-kappa B, SN-50; other NF-kappa B inhibitors, curcumin and pyrrolidine dithiocarbamate; and the proteasome inhibitor, MG-132. Gliotoxin also augmented dramatically the early (2-6 h) pro-apoptotic effects of tumor necrosis factor-alpha (TNF-alpha ) in neutrophils and unmasked the ability of TNF-alpha to induce eosinophil apoptosis. In neutrophils, TNF-alpha caused a gliotoxin-inhibitable activation of an inducible form of NF-kappa B, a response that may underlie the ability of TNF-alpha to delay apoptosis at later times (12-24 h) and limit its early killing effect. Furthermore, cycloheximide displayed a similar capacity to enhance TNF-alpha induced neutrophil apoptosis even at time points when cycloheximide alone had no pro-apoptotic effect, suggesting that NF-kappa B may regulate the production of protein(s) which protect neutrophils from the cytotoxic effects of TNF-alpha . These data shed light on the biochemical and molecular mechanisms regulating human granulocyte apoptosis and, in particular, indicate that the transcription factor NF-kappa B plays a crucial role in regulating the physiological cell death pathway in granulocytes.

    INTRODUCTION
Top
Abstract
Introduction
References

Neutrophilic and eosinophilic granulocytes originate from a common myeloid precursor; neutrophils are particularly active in the defense against invading micro-organisms whereas eosinophils serve in anti-parasitic defenses and play a role in allergic inflammation. The normally beneficial acute inflammatory response can become dysregulated and result in chronic inflammatory conditions where tissue damage arises in part due to the inappropriate liberation of inflammatory cell-derived histotoxic products. We have previously described a granulocyte clearance mechanism likely to be important in the normal control and resolution processes of inflammation whereby granulocytes must first undergo apoptosis (programmed cell death) before being phagocytosed and cleared by macrophages in situ (1, 2). Apoptosis also causes functional down-regulation of granulocytes and the retention of proteolytic granule contents to further limit the potential for granulocyte-mediated tissue damage (3, 4). While little is known about the physiological mechanisms involved in controlling granulocyte apoptosis, many in vitro studies have now shown that an array of pro-inflammatory cytokines and inflammatory mediators known to be present at inflamed sites inhibit the process of apoptosis in granulocytes (2-9). This has led to the suggestion that such agents act both to attract and activate inflammatory cells and also delay their removal. A notable exception to this rule, however, is TNF-alpha ,1 which, at early time points in neutrophil culture, causes acceleration of the constitutive rate of apoptosis (10).

Many inflammatory mediators regulate gene expression in target cells by influencing the activities of transcription factors such as nuclear factor-kappa B (NF-kappa B). NF-kappa B is composed of homo- or heterodimers of the Rel family proteins (p50/NFkappa B1, p52/NFkappa B2, p65/RelA, and cRel) which are sequestered in the cytoplasm by physical association with inhibitor proteins referred to as Ikappa B (11). Upon activation, the Ikappa B subunit is rapidly phosphorylated leading to its proteolytic breakdown permitting NF-kappa B to translocate to the nucleus (12, 13) where it regulates the activity of many genes involved in the inflammatory response, including those for pro-inflammatory cytokines. In a number of cell systems TNF-alpha has been shown to induce rapid activation of NF-kappa B, a response known to mediate a number of TNF-alpha induced cellular responses (reviewed in Refs. 14-16). However, whether the activation of NF-kappa B is involved in either the pro- or anti-apoptotic effects of TNF-alpha in granulocytes is currently unknown.

Whereas the inhibition of NF-kappa B has been shown to induce apoptosis in murine B cells (17), a completely opposite effect has been observed in other cell types where apoptosis is associated with activation of NF-kappa B (18). In addition, several groups have reported that inactivation of NF-kappa B increases the cytotoxic effects of TNF-alpha (19-21). In granulocytes, it remains uncertain whether NF-kappa B can be activated by inflammatory mediators, or is indeed present, in human neutrophils. For example, while MacDonald et al., (22) reported that lipopolysaccharide (LPS), TNF-alpha , and the chemotactic peptide N-formyl-methionyl-leucyl-phenylalanine all cause a marked activation of NF-kappa B, Browning et al., (23) found no such activity in these cells despite obvious NF-kappa B activation in peripheral blood mononuclear cells.

Gliotoxin, a member of the epipolythiodioxoperazine family of compounds (24), exhibits immunosuppressive activity both in vivo and in vitro. For example, gliotoxin has been shown to inhibit mitogen-induced proliferation of both T and B cells, induce macrophage and osteoclast apoptosis in vitro (25, 26), and cause thymocyte and spleen cell apoptosis in vivo (27). However, the biochemical and molecular mechanisms underlying these effects remain uncertain. Gliotoxin has, however, recently been shown to be a potent and specific inhibitor of NF-kappa B (28). We therefore used gliotoxin as a pharmacological tool to investigate the involvement of NF-kappa B in the regulation of granulocyte apoptosis. We demonstrate that gliotoxin causes a rapid and major induction of apoptosis in human peripheral blood granulocytes in vitro and up-regulates TNF-alpha -induced apoptosis in both neutrophils and eosinophils. In addition, we present evidence that these effects occur via a specific, non-toxic and caspase-controlled mechanism that is mediated by the ability of gliotoxin to inhibit an inducible form of NF-kappa B. The ability of other NF-kappa B inhibitors to cause a similar induction of apoptosis provides further evidence supporting the involvement of NF-kappa B in granulocyte apoptosis. Interestingly, the pro-apoptotic effect of TNF-alpha is enhanced by protein synthesis blockade suggesting that NF-kappa B activation results in the generation of an unidentified survival protein. These data therefore strongly suggest that NF-kappa B plays a key role in regulating both constitutive and TNF-alpha stimulated human granulocyte apoptosis.

    EXPERIMENTAL PROCEDURES

Neutrophil and Eosinophil Isolation and Culture

Neutrophils and eosinophils were isolated from the peripheral blood of normal donors by dextran sedimentation followed by centrifugation through discontinuous plasma-Percoll gradients (2, 29). Only neutrophil preparations with a neutrophil purity of >98% were used. Eosinophils were separated from contaminating neutrophils using an immunomagnetic separation step with sheep anti-mouse IgG-Dynabeads (Dynabeads M-450, Dynal, Merseyside, United Kingdom) coated with the murine anti-neutrophil antibody 3G8 (anti-CD16; a gift from Dr. J. Unkeless, Mount Sinai Medical School, New York). Cells were mixed with washed 3G8-coated Dynabeads at a bead:neutrophil ratio of 3:1 on a rotary mixer at 4 °C for 20 min, and the beads removed magnetically by two 3-min stationary magnetic contacts (Dynal Magnetic Particle Concentrator, MPC-1) to yield an a eosinophil population of >98% purity. After purification, cells were washed twice in phosphate-buffered saline without calcium and magnesium and once in phosphate-buffered saline before resuspending in Iscove's DMEM (Life Technologies, Paisley, UK) with 10% autologous serum. Both cell types were cultured in flat-bottomed Falcon flexible wells (Becton Dickinson, Oxford, UK) at 37 °C in a 5% CO2 atmosphere; neutrophils at a concentration of 5 × 106/ml and eosinophils at 2 × 106/ml. Cells were cultured in the absence or presence of test agents as described in the figure legends. All experiments were performed at least 3 times and each treatment done in triplicate.

Assessment of Granulocyte Apoptosis

Morphology-- Cells were cyto-centrifuged, fixed in methanol, stained with Diff-QuikTM, and counted using oil immersion microscopy (×100 objective) to determine the proportion of cells with highly distinctive apoptotic morphology (5, 7, 10). At least 500 cells were counted per slide with the observer blinded to the experiment conditions. The results were expressed as the mean % apoptosis ± S.E.

Annexin V Binding-- A separate and independent assessment of apoptosis was performed by flow cytometry using fluorescein isothiocyanate-labeled recombinant human annexin V that binds to phosphatidylserine exposed on the surface of apoptotic cells. Stock annexin V (Bender MedSystems, Vienna, Austria) was diluted 1:200 with binding buffer and then added (25 µl) to 75 µl of the recovered cell samples. Following a 10-min incubation at 4 °C, these samples were fixed by the addition of 100 µl of 3% paraformaldehyde in phosphate-buffered saline before analysis using an EPICS Profile II (Coulter Electronics, Luton, UK).

DNA Fragmentation Assay-- DNA was extracted as described previously (10). Briefly, 2 × 106 neutrophils were taken after the indicated treatment and lysed in 500 µl of lysis buffer (6 M guanidine hydrochloride, 50 mM Tris-HCl, pH 8.0, and 0.1% N-lauroyl sarcosine) at 4 °C and the nucleic acids extracted by the addition of an equal volume of 10 mM Tris-HCl, pH 8.0-saturated phenol:chloroform mixture (50:50, v/v). The resulting emulsion was centrifuged at 12,000 × gav for 10 min at room temperature and the aqueous phase removed and precipitated with 0.6 volumes of isopropyl alcohol at room temperature. The precipitated nucleic acids were then pelleted by centrifugation at 10,000 × gav for 5 min and re-dissolved in 50 µl of TE buffer (10 mM Tris-Cl, 1 mM EDTA, pH 8.0) containing 50 µg/ml RNase A. The fragmented DNA was separated by agarose gel electrophoresis on a 1.4% (w/v) agarose (Flowgen, UK) 0.5 × TBE (10 mM Trizma (Tris base), 10 mM boric acid, and 1 mM EDTA, pH 8.3) gel. The gel was run for 2 h at 75 V and stained using ethidium bromide (0.5 µg/ml). The UV transilluminated image was printed by digital thermal printing using a GS7600 gel documentation system (UVP Products, UK).

Assessment of Cell Membrane Integrity

Since apoptotic neutrophils and eosinophils maintain the integrity of their plasma membrane, assessment of granulocyte necrosis can be determined by the ability of cells to exclude the vital dye trypan blue and also by flow cytometry using propidium iodide staining. Samples (150 µl of cells at 2 × 106/ml) were centrifuged and resuspended in 150 µl of propidium iodide solution (33 µg/ml propidium iodide in phosphate-buffered saline containing 1.67 mg/ml RNase). The profiles of heat-treated (necrotic cells) from the same samples were used as controls.

Electrophoretic Mobility Shift Assay (EMSA)

EMSAs were carried out as described by the manufacturer (Promega Corp, Southampton, UK). Nuclear extracts were prepared from 5 × 106 cells using a modification of the method of Dignam et al. (30). Briefly, pelleted cells were resuspended in 200 µl of hypotonic buffer (buffer A: 10 mM Tris-HCl, pH 7.8, 1.5 mM EDTA, 10 mM KCl, 0.5 mM dithiothreitol, 1 µg/ml aprotinin, leupeptin, and pepstatin A, 1 µM 4-(2-aminoethyl)benzenesulfonyl fluoride, 1 mM sodium orthovanadate, 0.5 mM benzamidine, and 2 mM levamisole) and placed on ice for 10 min. Following the addition of 0.1 volumes of 10% Nonidet P-40 (W/v) the cells were vortexed briefly and centrifuged at 12,000 × gav for 2 min at 4 °C. The supernatant was discarded and the pellet washed in 100 µl of buffer A minus Nonidet P-40 and re-centrifuged. The pelleted nuclei were then resuspended in 50 µl of hypertonic buffer (buffer B: 20 mM Tris-HCl, pH 7.8, 150 mM NaCl, 50 mM KCl, 1.5 mM EDTA, 5 mM dithiothreitol, 1 µg/ml aprotinin, leupeptin, and pepstatin A, 1 µM 4-(2-aminoethyl)benzenesulfonyl fluoride, 1 mM sodium orthovanadate, 0.5 mM benzamidine, and 2 mM levamisole) and stored at -80 °C until use.

Nuclear extracts (approximately 2 µg of protein, 7 × 105 cell equivalent, in 7 µl) were incubated in binding buffer (4% glycerol, 1 mM MgCl2, 0.5 mM EDTA, 0.5 mM dithiothreitol, 50 mM NaCl, 10 mM Tris-HCl, pH 7.5, with 50 µg/ml poly(dI-dC)·poly(dI-dC) (Pharmacia Biotech, UK) with 17 fmol of gamma -32P-labeled double stranded oligonucleotide containing the decameric kappa B-binding site (3000 Ci/mmol; Promega Corp., Southampton, UK) at 22 °C for 20 min prior to addition of 5 µl of loading buffer (0.01% (w/v) bromphenol blue, 20% (w/v) Ficoll 400TM, and 1 mM EDTA). Samples were loaded onto an 8% (w/v) native acrylamide gel (Protean IIxi, Bio-Rad, Hemel Hempstead, UK) in 0.5 × TBE buffer and run at 250 V for 2 h. The gel was then dried onto 3MM paper (Whatman UK, Maidstone, UK) and BioMax MS-1 x-ray film (Kodak, Anachem, Luton, UK) was exposed to the gel. Processed films were analyzed using the GrabIt and GelPlate software (UVP, Orme Technologies, UK) and the data expressed as a percent of the control value for each experiment.

Materials

Further specific materials were obtained as follows: curcumin, gliotoxin, LPS (Escherichia coli 0127:B8), methylthiogliotoxin, and PDTC (Sigma Co., Poole, UK); recombinant human TNF-alpha (R & D Systems, Abingdon, Oxon, UK); zVAD-fmk (Bachem (UK) Ltd., Saffron Walden, UK). The proteasome inhibitor MG-132 (N-cbz-Leu-Leu-leucinal), and the NF-kappa B inhibitory peptides SN50 and SN50M (Biomol, Affinity Research Products, Mamhead, UK). All other reagents were obtained from Sigma, UK, and were of the highest purity.

Statistical Analysis

The results are expressed as mean ± S.E. of the number (n) of independent experiments each using cells from separate donors with each treatment performed in triplicate. Statistical analysis was performed by ANOVA with comparisons between groups made using the Newman-Kuels procedure. Differences were considered significant when p < 0.05.

    RESULTS

Effect of Gliotoxin on Neutrophil Apoptosis-- As shown in Fig. 1 gliotoxin caused a rapid and profound induction of neutrophil apoptosis in vitro which was both concentration (e.g. at 6 h EC50 = 76.1 ± 22.1 ng/ml, Fig. 1A), and time-dependent (Fig. 1, A and B). Hence using a maximally effective gliotoxin concentration of 1 µg/ml, apoptosis was readily apparent within 2 h and reached 100% by 6 h. At 20 h, when the rate of constitutive neutrophil apoptosis was 58.7 ± 2.9%, gliotoxin caused 100% apoptosis at all concentrations greater than 0.1 µg/ml. The inactive analogue of gliotoxin, methylthiogliotoxin, did not affect the constitutive rate of neutrophil apoptosis at any of the time points studied (Fig. 1B). Neither gliotoxin nor its inactive analogue, methylthiogliotoxin, caused cell necrosis since less than 1% of the cells were permeable to the vital dye trypan blue.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 1.   Time course and concentration-response curve for the effect of gliotoxin on human neutrophil apoptosis. Human neutrophils (5 × 106/ml) were cultured at 37 °C in Iscove's DMEM containing 10% autologous serum and treated with the indicated concentrations of gliotoxin. At the time periods indicated, the cells were resuspended and cytocentrifuge preparations made. These were fixed and stained, and apoptosis was assessed morphologically. A, represents the effect of gliotoxin (0.001-30 µg/ml) on neutrophil apoptosis after 2, 6, or 20 h of culture. B, represents the effect of methylthiogliotoxin (30 µg/ml) or gliotoxin (30 µg/ml) on neutrophil apoptosis after 2, 6, or 20 h culture. All values represent mean ± S.E. of n = 3 experiments, each performed in triplicate. Where not shown, S.E. values are less than 2% of the mean.

Gliotoxin Acts Synergistically with TNF-alpha to Stimulate Neutrophil Apoptosis-- In contrast to many other hematopoetic cells, human neutrophils appear highly resistant to the induction of apoptosis induced by certain agents, for example, incubation with Ca2+ ionophores (31, 32), cAMP elevating agents (33), corticosteroids (9), and LPS (7) causes inhibition of apoptosis as does hypoxia (34). Furthermore, while TNF-alpha and Fas-L can induce neutrophil apoptosis, this effect is modest and transient, and in the case of TNF-alpha abolished if the cells are initially primed with platelet-activating factor or LPS (10, 35). We therefore sought to determine the effect of gliotoxin on TNF-alpha -induced apoptosis in neutrophils. These experiments were performed deliberately at a very early time point (2 h) when the independent pro-apoptotic effects of even a maximally effective concentration of TNF-alpha (10 ng/ml) (10) and gliotoxin (1 µg/ml; Fig. 1A) are only just apparent. As shown in Fig. 2A, a major synergy was observed between these agents for the induction of apoptosis which was apparent even at gliotoxin concentrations as low as 3 ng/ml. Hence, a concentration of 0.1 µg/ml gliotoxin in combination with TNF-alpha (10 ng/ml) caused almost 100% apoptosis at 2 h. With gliotoxin alone, only 6% apoptosis was noted at 2 h, with just over 65% at 6 h (Fig. 1A). Again, methylthiogliotoxin had no effect on constitutive apoptosis or TNF-alpha -induced apoptosis at 2 h (Fig. 2B). The level of necrosis in cells from each treatment was assessed by trypan blue exclusion; all values were <1% (data not shown).


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 2.   The effect of gliotoxin, methylthiogliotoxin, and TNF-alpha on human neutrophil apoptosis. Human neutrophils (5 × 106/ml) were cultured at 37 °C in Iscove's DMEM containing 10% autologous serum and treated with the indicated concentrations of gliotoxin, plus or minus TNF-alpha . After 2 h of culture, the cells were resuspended and cytocentrifuge preparations made. These were fixed and stained, and apoptosis was assessed morphologically. A, represents the effect of gliotoxin (0.001-30 µg/ml) on TNF-alpha (10 ng/ml)-induced neutrophil apoptosis. B, represents the effect of methylthiogliotoxin (30 µg/ml) or gliotoxin (30 µg/ml), plus or minus TNF-alpha (10 ng/ml). All values represent mean ± S.E. of n = 3 experiments, each performed in triplicate. Where not shown, S.E. values are less than 2% of the mean.

The genuine nature of both the intrinsic pro-apoptotic effect of gliotoxin and the dramatic synergy with TNF-alpha was assessed by comparing the quantitative morphological effects of these agents with their effects on annexin V binding and DNA fragmentation. The changes from normal cell morphology to apoptotic morphology are clearly seen in Fig. 3A; where non-apoptotic neutrophils contain a multilobed nucleus and the apoptotic cells have a shrunken appearance with pyknotic nuclei. These data can be compared with Fig. 3B, where the annexin V "low peak" represents non-apoptotic cells and the annexin V "high peak" represents apoptotic cells since the fluorescein isothiocyanate-labeled annexin V binds in the presence of Ca2+ to phosphatidylserine exposed on the outer membrane of apoptotic cells. Although control cells at 2 h exhibit low rates of apoptosis, the small increase in annexin V positive cells observed with TNF-alpha and gliotoxin alone is again dramatically augmented when the cells are cultured in the presence of both reagents together. Analysis by DNA fragmentation also demonstrates that cells cultured alone or in combination with the above reagents exhibit the classical "ladder" of DNA fragmentation associated with apoptosis (Fig. 3C).


View larger version (48K):
[in this window]
[in a new window]
 


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 3.   The effect of gliotoxin and TNF-alpha on neutrophil morphology, phosphatidylserine expression, and cell membrane integrity. A, cytocentrifuge preparations of human neutrophils incubated for 2 h in Iscove's DMEM at 37 °C containing 10% autologous serum alone (control), plus TNF-alpha , plus gliotoxin, or with both TNF-alpha and gliotoxin at the concentrations shown. Neutrophils treated with both reagents all clearly show apoptotic morphology. B, after 2 h in culture at 37 °C, cells treated with Iscove's DMEM, TNF-alpha (10 ng/ml), gliotoxin (0.1 µg/ml), or with both TNF-alpha plus gliotoxin were resuspended and incubated with fluorescein isothiocyanate-labeled recombinant human annexin V to determine phosphatidylserine expression. The cells were then fixed and analyzed using an EPICS Profile II. Mean fluorescence values are shown for a minimum of 5,000 cells for each condition. C, DNA fragmentation in human neutrophils treated with TNF-alpha (10 ng/ml), gliotoxin (0.1 µg/ml), or both reagents together for 2 h. DNA was prepared as detailed under "Experimental Procedures"; lane 1, DNA marker (1-kilobase ladder); lane 2, freshly isolated neutrophils; lane 3, control; lane 4, TNF-alpha ; lane 5, gliotoxin, 2 h; lane 6, co-culture with gliotoxin and TNF-alpha ; lane 7, DNA marker (1-kilobase ladder). D, to assess cell membrane integrity, cells treated with both TNF-alpha (10 ng/ml) and gliotoxin (0.1 µg/ml) for 4 h, which induced 100% apoptosis even by 2 h, were resuspended and incubated with propidium iodide, fixed, and analyzed using an EPICS Profile II (solid line). An aliquot of cells from this preparation was heated as indicated under "Experimental Procedures" to produce 100% necrosis (dotted line). Mean fluorescence values are shown for a minimum of 5,000 cells for each condition.

Combined Gliotoxin and TNF-alpha Treatment Does Not Cause Necrosis-- Although our initial studies using trypan blue as a marker of plasma membrane integrity indicated that gliotoxin, both in the presence and absence of TNF-alpha , induced a purely apoptotic form of cell death, we felt it was important to validate this further by assessing necrosis in an independent manner using propidium iodide staining detected by flow cytometry. Fig. 3D shows the profile of neutrophils 4 h following treatment with gliotoxin (0.1 µg/ml) and TNF-alpha (10 ng/ml) where, despite apoptotic rates of 100%, almost all cells showed low fluorescence indicating that the cell membrane had remained intact. As a positive control, cells cultured initially with TNF-alpha and gliotoxin were then heat-treated (60 °C, 5 min) to ensure 100% necrosis. This resulted in a uniform and major increase in propidium iodide staining (Fig. 3D). These data coincide completely with the results obtained with trypan blue staining and confirm that these cells had undergone apoptotic cell death and were not necrotic.

Gliotoxin Inhibits the Survival Effect of LPS-- To investigate whether gliotoxin could modulate the effects of LPS on the rate of neutrophil apoptosis we performed a series of experiments where neutrophils were cultured for 2, 3, 4, and 20 h in the presence of LPS, gliotoxin, and a combination of LPS plus gliotoxin and apoptosis assessed morphologically (Fig. 4). As reported previously (7) LPS caused an inhibition of neutrophil apoptosis at 20 h when compared with control cells. Interestingly, the suppressive effect of LPS was prevented by the strong pro-apoptotic effect of gliotoxin. In addition, unlike co-culture of gliotoxin plus TNF-alpha , no synergistic induction of apoptosis was observed when LPS was cultured in the presence of gliotoxin (Fig. 4).


View larger version (11K):
[in this window]
[in a new window]
 
Fig. 4.   The effect of gliotoxin alone and in the presence of LPS on human neutrophil apoptosis. Human neutrophils (5 × 106/ml) were cultured in Iscove's DMEM at 37 °C containing 10% autologous serum alone and treated with gliotoxin (0.1 µg/ml), with or without LPS (1 µg/ml). At the time periods indicated, the cells were resuspended and cytocentrifuge preparation made. These were fixed and stained, and apoptosis was assessed morphologically. All values represent mean ± S.E. of n = 3-5 experiments, each performed in triplicate. Where not shown, S.E. values are less than 2% of the mean.

Gliotoxin Unmasks the Ability of TNF-alpha to Induce Eosinophil Apoptosis-- To explore whether the pro-apoptotic effect of gliotoxin was restricted to neutrophils, a similar set of experiments were performed using human peripheral blood eosinophils isolated from mildly atopic individuals. While these cells display a similar capacity to undergo constitutive apoptosis when aged in vitro, this process is much slower than that observed for the neutrophil and is differentially regulated being, for example, stimulated rather than inhibited by corticosteroids (9). We therefore investigated the effect of gliotoxin on eosinophil apoptosis at 4 h in the presence and absence of TNF-alpha . The results, shown in Fig. 5, A and B, demonstrated that gliotoxin caused a similar induction of apoptosis in eosinophils (EC50 = 0.37 ± 0.22 µg/ml) and caused a synergistic increase in the rate of apoptosis when the cells were co-cultured with TNF-alpha . This latter observation was all the more striking since in eosinophils, TNF-alpha treatment alone had no effect on the rate of apoptosis (Fig. 5B and data not shown). Hence, almost 100% apoptosis was observed using a gliotoxin concentration of 0.1 µg/ml plus TNF-alpha at a time point of 4 h. In comparison, eosinophils cultured in the absence of gliotoxin would normally show only 40% apoptosis at a 40-h time point (2, 36). Necrosis in these cells was <2% and the inactive analogue of gliotoxin had no effect on either the constitutive rate of apoptosis alone or in conjunction with TNF-alpha (data not shown). As with the neutrophils, eosinophils demonstrated classic apoptotic morphology when treated with these agents.


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 5.   The effect of gliotoxin alone and in the presence of TNF-alpha on human eosinophil apoptosis. Human eosinophils (2 × 106/ml) were cultured in Iscove's DMEM at 37 °C containing 10% autologous serum alone and treated with the indicated concentrations of gliotoxin with or without TNF-alpha . At the time periods indicated, the cells were resuspended and cytocentrifuge preparation made. These were fixed and stained, and apoptosis was assessed morphologically. A, represents the effects of gliotoxin (0-3 µg/ml) on eosinophil apoptosis after 4 h of culture. B, represents the effects gliotoxin (0-0.3 µg/ml) with or without TNF-alpha (10 ng/ml) on eosinophil apoptosis after a 4-h culture. All values represent mean ± S.E. of n = 3 experiments, each performed in triplicate. Where not shown, S.E. values are less than 2% of the mean.

Gliotoxin Causes Inhibition of an Inducible Isoform of NF-kappa B-- Recent studies have indicated that NF-kappa B may play an important role in regulating the rate of apoptosis in certain transformed cells (17, 18). Hence, because gliotoxin has been reported to act as a specific inhibitor of NF-kappa B (28) experiments were designed to identify and characterize the expression of this transcription factor in human neutrophils and determine if gliotoxin could inhibit such activity. Preliminary time course data established 90 min as the optimal time to examine basal, gliotoxin, and TNF-alpha regulated NF-kappa B activity in these cells (data not shown). Of note, this time point also coincided with the onset of the biologically observable effect of gliotoxin. As shown in Fig. 6, A-C, NF-kappa B EMSAs performed on neutrophil nuclear extracts indicated the presence of 3 discrete bands in these gels. To ascertain which of these bands were specifically NF-kappa B, an excess of unlabeled probe was included in the labeling reaction to displace specific binding; as shown in Fig. 6C, two NF-kappa B bands were identified and designated A and B. 


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 6.   Effect of gliotoxin and TNF-alpha on NF-kappa B mobilization. A, EMSA of nuclear extracts from neutrophils treated with control buffer: lane 1, TNF-alpha (10 ng/ml); lane 2, gliotoxin (1 µg/ml); lane 3, gliotoxin (0.1 µg/ml); lane 4, and TNF-alpha (10 ng/ml) plus gliotoxin (0.1 µg/ml); lane 5, for 90 min at 37 °C. B, EMSA showing the up-regulation of the inducible isoform (band A) by LPS (a known inhibitor of neutrophil apoptosis) after 20 min culture: lane 1, control; lane 2, LPS (100 ng/ml); and lane 3, LPS (100 ng/ml) plus gliotoxin (0.1 µg/ml). C, EMSA showing displacement of specific NF-kappa B bands by excess cold oligonucleotide probe; lane 1, control; lane 2, TNF-alpha (10 ng/ml); lane 3, TNF-alpha (10 ng/ml) plus 50-fold excess cold oligonucleotide; lane 4, TNF-alpha (10 ng/ml) plus 100-fold excess cold oligonucleotide. Only the bands marked A and B are specific. D, densiometry scanning of band A from the EMSA shown in A. This shows the reduction of an inducible isoform of NF-kappa B by gliotoxin (a = 1 µg/ml; b = 0.1 µg/ml), and further inhibition by co-treatment with TNF-alpha plus gliotoxin (b).

In both TNF-alpha (10 ng/ml, 0-90 min) and LPS (1 µg/ml, 0-120 min) treated cells, no change in the intensity of band B was observed (Fig. 5, A and B, and data not shown). This, together with its strong expression in freshly prepared untreated neutrophils suggests that this band represents a form of constitutively active NF-kappa B. However, band A was markedly up-regulated by TNF-alpha (Fig. 6, A and C), and as shown in Fig. 6A, gliotoxin caused both a concentration-dependent inhibition of this NF-kappa B activity and abolished the TNF-alpha stimulated increase in this band. As shown in Fig. 6D, densiometric analysis of these data confirmed that co-treatment of neutrophils with TNF-alpha and gliotoxin at a maximal effective functional concentration of 0.1 µg/ml (Fig. 2A) inhibited this band more than treatment with gliotoxin alone. The results in Fig. 6, A and D, confirm that the basal level of NF-kappa B activity in control samples at 90 min was inhibited by gliotoxin treatment; a finding that was observed at all other time points tested.

Further evidence that strongly supports the suggestion that NF-kappa B inhibition is linked to the induction of neutrophil apoptosis is provided by the fact that the cell permeable NF-kappa B inhibitory peptide, SN50 (37), also increased the rate of constitutive neutrophil apoptosis despite the fact that less than 5% of the peptide reportedly enters the cell (37). Hence at 6 h, the SN50 peptide increased neutrophil apoptosis from 4.7 ± 1.2 to 15.0 ± 3.2% (n = 3; p < 0.05), whereas the less active peptide SN50M only increased apoptosis from 4.7 ± 1.2 to 5.6 ± 0.8% (n = 3). Similar effects on neutrophil apoptosis were seen at 20 h and eosinophil apoptosis at 20 and 40 h (Table I and data not shown). Other agents known to inhibit NF-kappa B similarly induced neutrophil apoptosis. The proteasome inhibitor, MG-132 (38) and the NF-kappa B inhibitor curcumin (39) caused a time-dependent induction of neutrophil apoptosis (Fig. 7A). PDTC, that acts as both a radical scavenger and inhibitor of NF-kappa B activation (40), also caused a significant induction of apoptosis when cultured with neutrophils for 20 h (Fig. 7B). Furthermore, treating neutrophils with LPS (100 ng/ml, 20 min) which we have previously reported to induce a profound inhibition of neutrophil apoptosis (7) was found to cause the appearance of this inducible isoform of NF-kappa B (Fig. 6B); and this induction could be inhibited by gliotoxin (0.1 µg/ml).

                              
View this table:
[in this window]
[in a new window]
 
Table I
The effect of NF-kappa B inhibitory peptides on human neutrophil apoptosis
Human neutrophils (5 × 106/ml) were resuspended in Iscove's DMEM without autologous serum and treated with control buffer, SN50 (100 µg/ml), and SN50M (100 µg/ml). After 15 min at 37 °C, 10% autologous serum (final concentration) was added, and after 6 and 20 h of culture, the cells were resuspended and cytocentrifuge preparations made. These were fixed and stained, and apoptosis was assessed morphologically. All values are from n = three separate experiments, each performed in triplicate.


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 7.   Effect of other NF-kB inhibitors on neutrophil apoptosis. Human neutrophils (5 × 106/ml) were cultured at 37 °C in Iscove's DMEM containing 10% autologous serum and treated with the indicated reagent. A, neutrophils were treated with MG 132 (20 µM) and curcumin (20 µM) at the time periods indicated; B, neutrophils were treated with MG-132 (100 µM), curcumin (20 µM), and PDTC (300 µM) for 20 h. After incubation, the cells were resuspended and cytocentrifuge preparations made. These were fixed and stained, and apoptosis was assessed morphologically. All values represent mean ± S.E. of n = three to six experiments, each performed in triplicate. Where not shown, S.E. values are less than 2% of the mean.

Induction of Apoptosis by Gliotoxin Is Dependent on Activation of the Caspase-cascade Pathway-- We have recently demonstrated that the early pro-apoptotic effects of TNF-alpha in human neutrophils requires activation of both TNF-55 and TNF-75 receptor subtypes and thereby differs significantly from the priming effect of TNF-alpha which is signaled via the TNF-p55 receptor alone (10). To determine whether the pro-apoptotic effects of gliotoxin and the marked synergism displayed by TNF-alpha and gliotoxin were mediated via activation of the caspase pathway, we co-incubated neutrophils with TNF-alpha , gliotoxin, and zVAD-fmk. At 2 h, zVAD-fmk completely inhibited the increase in apoptosis induced by gliotoxin, TNF-alpha and by both factors together (Fig. 8A). This demonstrates that apoptosis induced by both factors alone, or together, is dependent on caspase activation.


View larger version (12K):
[in this window]
[in a new window]
 
Fig. 8.   Effect of the caspase inhibitor, zVAD-fmk, and the protein synthesis inhibitor, cycloheximide, on gliotoxin, TNF-alpha , or gliotoxin plus TNF-alpha -induced human neutrophil apoptosis. Human neutrophils (5 × 106/ml) were cultured in DMEM containing 10% autologous serum and treated with the indicated reagents. After 2 h of culture, the cells were resuspended and cytocentrifuge preparation made. These were fixed and stained, and apoptosis was assessed morphologically. A, represents the effects of zVAD-fmk (100 µM) on gliotoxin (0.1 µg/ml)-, TNF-alpha (10 ng/ml)-, or gliotoxin plus TNF-alpha -induced neutrophil apoptosis. B, represents the effects of cycloheximide (5 µM) on gliotoxin (0.1 µg/ml)-, TNF-alpha (10 ng/ml)-, or gliotoxin plus TNF-alpha -induced neutrophil apoptosis. All values represent mean ± S.E. of n = three experiments, each performed in triplicate. Where not shown, S.E. values are less than 2% of the mean.

Gliotoxin May Enhance TNF-alpha -induced Apoptosis by Inhibiting Production of a Survival Factor-- Taken together, the above results suggest that activation of an inducible form of NF-kappa B may inhibit or restrain the pro-apoptotic effects of TNF-alpha which are mediated by the parallel activation of the caspase pathway. The possibility that this most likely reflects the production of a protein or proteins which act to suppress the activation of the caspase pathway and thus protect granulocytes from the cytotoxic effects of this cytokine was investigated by incubating neutrophils with TNF-alpha and cycloheximide, a protein synthesis inhibitor. As illustrated in Fig. 8B, cycloheximide used specifically at a concentration (5 µM) that alone had almost no effect on neutrophil apoptosis at 2 h, caused a synergistic increase in the level of apoptosis when neutrophils were co-cultured with TNF-alpha . This supports the view that TNF-alpha treatment indeed results in the generation of a survival protein that protects these cells from the TNF receptor-caspase-dependent induction of apoptosis by TNF-alpha .

    DISCUSSION

We have demonstrated that gliotoxin, but not its inactive derivative methylthiogliotoxin, (a) induces a direct time- and concentration-dependent increase in the rate of constitutive apoptosis in both neutrophils and eosinophils, (b) enhances the pro-apoptotic effect of TNF-alpha in neutrophils, and (c) reveals the cytotoxic effects of TNF-alpha in eosinophils. In these studies extreme care was taken to ensure that gliotoxin, at all time points and concentrations studied, was non-toxic and caused genuine apoptosis that was indistinguishable from later constitutive apoptosis. The similar effects of gliotoxin in both neutrophils and eosinophils and the same concentration of gliotoxin (0.1 µg/ml) required for maximal enhancement of the pro-apoptotic effects of TNF-alpha , suggests that an identical underlying mechanism is regulating the induction of cell death in both these cell types. However, although inhibition of basal NF-kappa B activity may be involved in neutrophil apoptosis when induced by gliotoxin alone (Fig. 1) since gliotoxin appears to block basal levels of NF-kappa B activity (Fig. 6, A and D), only the expression of the inducible NF-kappa B isoform is down-regulated before the onset of cell death driven by the combined effects of TNF-alpha and gliotoxin (Fig. 6). Even in control neutrophils incubated for 20 h, where the constitutive rate of apoptosis is approximately 70%, the density of the constitutive NF-kappa B band was unaffected (data not shown). These differences in the inducible and constitutive forms of NF-kappa B most likely reflects differential regulation of activation, for example, by the involvement of different isoforms of the inhibitory Ikappa B subunit, or that the constitutively active NF-kappa B is formed from a different set of dimers from the classical RelA/p50 heterodimer. It has recently been demonstrated that neutrophils contain c-Rel, p50, and p105 (the p50 precursor protein) as well as Rel-A (22, 41). The inducible band we observed has also been reported to be up-regulated in neutrophils by phagocytosis of IgG opsonized yeast particles (42), and has been shown to consist mainly of Rel-A/p50 heterodimers and possibly a small amount of c-Rel (42). In that study, phagocytosis of these particles did not affect the activity of the constitutive complex. In addition, it has recently been reported that NF-kappa B becomes activated, via a mechanisms not involving oxidant generation, when neutrophils phagocytose bacteria (43).

Because NF-kappa B is also activated by certain pro-apoptotic stimuli such as TNF-alpha , this transcription factor has been considered as a possible regulator of cell death. Hence, in some T cell clones, activation of NF-kappa B appears to correlate with the onset of apoptosis (18). However, NF-kappa B activation has clearly been shown to be anti-apoptotic in HT 1080 fibrosarcoma cells (21) and TNF-alpha induced NF-kappa B activation prevents cell death in HeLa and MCF7 cells (44). Here we show for the first time that in a non-transformed cell namely the neutrophil, inhibition of an inducible form of NF-kappa B is related to the induction of apoptosis.

Several mechanisms, aside from NF-kappa B inhibition, have been proposed for the pro-apoptotic actions of gliotoxin in other cells. Sutton et al. (45) have shown that although this fungal metabolite did not affect intracellular calcium levels, there was a correlation between increases in cAMP levels and apoptosis in gliotoxin-treated splenocytes. However, we and others have previously demonstrated that agents that elevate intracellular cAMP inhibit apoptosis in both neutrophils and eosinophils (33, 46). It has also been suggested that protein kinase A-dependent phosphorylation of histone H3 correlates with gliotoxin-induced apoptosis in thymocytes (47), but again in neutrophils, activation of protein kinase A inhibits apoptosis (33). Although gliotoxin has been reported to inhibit protein synthesis (48) it is highly unlikely that this mechanism is directly responsible for its pro-apoptotic effects: first, gliotoxin induces apoptosis in thymocytes whereas inhibition of protein synthesis by cycloheximide inhibits thymocyte apoptosis. Second, since NF-kappa B activation is involved in the control of multiple genes, many of which encode for inflammatory mediator synthesis, inactivation of NF-kappa B would therefore be expected to inhibit protein synthesis. Third, while protein synthesis inhibitors do up-regulate the rate of constitutive cell death in granulocytes, the kinetics of this response are very different to those observed with gliotoxin. For example, Whyte et al. (49) have reported that cycloheximide (50 µM) and actinomycin D (1 µM) induce apoptosis in approximately 30% of neutrophils by 6 h. In our experiments, gliotoxin (0.1 µg/ml), induces a rate of almost twice this, whereas 1.0 µg/ml gliotoxin induced 100% neutrophil apoptosis by this time point (see Fig. 1A). Likewise, our own results with cycloheximide indicate that protein synthesis inhibition alone does not affect the rate of neutrophil apoptosis at 2 h whereas gliotoxin alone produced almost 15% apoptosis over this period (Figs. 1A and 8B). While gliotoxin inhibits NF-kappa B, cycloheximide and actinomycin D have been shown in several systems to activate this transcription factor (50, 51). Although both cycloheximide and gliotoxin give a similar synergistic pro-apoptotic response with TNF-alpha , this suggests that different mechanisms must be involved. However, while gliotoxin may prevent synthesis of a protective protein inducible by NF-kappa B activation, cycloheximide would also preclude synthesis of such a protein so that in both cases the cells would be sensitive to the pro-apoptotic effects of TNF-alpha . It is of interest to note that granulocytes do have the capacity to synthesize proteins, albeit in a limited capacity (49). We believe that this synthetic capacity will be directed toward resolution of the inflammatory response with the generation of protein(s) that affect the apoptotic program of inflammatory cells.

Our results indicate that the inducible isoform of NF-kappa B disappears from the gliotoxin-treated granulocyte nucleus just before the onset of stimulated apoptosis. The possibility that these events are causally related is supported by the following observations: (i) the synthetic cell-permeable peptide SN50 (37), a known inhibitor of NF-kappa B, also induces apoptosis in neutrophils and eosinophils; (ii) other agents that inhibit NF-kB activation, namely PDTC and curcumin as well as the proteasome inhibitor MG-132 also cause an induction of granulocyte apoptosis; (iii) the kinetics for gliotoxin-mediated inhibition of NF-kappa B match those for the onset of induction of apoptosis; (iv) LPS which stimulates NF-kappa B activity prolongs neutrophil and eosinophil survival; and (v) that gliotoxin sensitizes both neutrophils and eosinophils to the pro-apoptotic effects of TNF-alpha . Indeed, our studies provide the first plausible explanation for the modest and temporally constrained apoptotic response of neutrophils to TNF-alpha and the observation that pretreatment with LPS, PAF or granulocyte/macrophage-colony stimulating factor, abolishes the cytotoxic effect of this cytokine (10). Indeed, this latter point is of particular relevance when investigating the pro-apoptotic effect of TNF-alpha in neutrophils since pre-treatment of these cells causes a rapid decrease of both TNF-alpha receptors subtypes from the surface membrane (10). This phenomenon, together with the fact that the effects of SN50 are, at best, modest due to limited access of the peptide to its intracellular target (37) and the requirement for pretreatment with the peptide, precluded accurate assessment of SN50 on TNF-alpha induced apoptosis in neutrophils.

When neutrophils were co-cultured with LPS and gliotoxin, gliotoxin failed to render LPS pro-apoptotic despite the fact that LPS induced survival was inhibited by gliotoxin (Fig. 4). These results suggest that LPS does not trigger a death pathway in neutrophils but stimulates a NF-kappa B-mediated survival pathway i.e. when NF-kappa B activation is blocked, LPS is no longer capable of delaying apoptosis. The precise intracellular mechanisms by which the NF-kappa B inhibitors used in this study induce apoptosis are unknown and is the subject of further investigation. For example, it would be of interest to perform an in-depth analyses of the effect of gliotoxin and the other agents on the degradation of the inhibitory subunit Ikappa B, especially since Pahl et al. (28) reported that gliotoxin appeared to prevent Ikappa B degradation rather than mediate its effect at the level of DNA binding.

In a number of immune cells NF-kappa B activation by agents such as TNF-alpha has been shown to play a central role in regulating the genes for inflammatory cytokines such as granulocyte/macrophage-colony stimulating factor and TNF-alpha itself (14). The importance of this response in vivo is that many of these factors inhibit granulocyte apoptosis and may therefore delay inflammatory resolution by enhancing the longevity of these cells. Indeed, a positive-feedback loop may exist since many of these inflammatory mediators which protect against apoptosis in neutrophils and eosinophils also activate NF-kappa B (7). Conversely, we have recently shown that NO, a known inhibitor of NF-kappa B (52, 53), is a potent inducer of apoptosis in neutrophils (54). Our current results suggest that the activation of an inducible form of NF-kappa B represents a powerful survival mechanism in granulocytes, and that when this pathway is inhibited, in both neutrophils and eosinophils, these cells undergo a greatly augmented rate of apoptotic cell death. It is possible that NF-kappa B performs a similar function in other cell types that undergo apoptosis in response to gliotoxin.

Enhanced cytotoxic responses to TNF-alpha have also been demonstrated in cells where NF-kappa B is genetically deficient or inactivated (19-21) and hepatocytes from Rel-A null mice are known to undergo apoptosis causing death in utero (55). Embryonic fibroblasts and macrophages from Rel-A-deficient mice also showed dramatic loss of viability when treated with TNF-alpha leading to the suggestion that Rel-A regulates a protective mechanism against the cytotoxic effects of TNF-alpha . It would be of interest to investigate the effects of TNF-alpha and gliotoxin on granulocytes isolated from mice deficient in Rel A; it would be reasonable to predict that TNF-alpha will induce a rapid cell death and gliotoxin and other NF-kappa B inhibitors would not have a dramatic effect on the rate of granulocyte apoptosis. Although our experiments indicate that gliotoxin does not inhibit the constitutive form of NF-kappa B, at least at early time points, it does inhibit the activation of an inducible isoform of NF-kappa B, which most likely consists of heterodimers containing the Rel-A/p65 protein and therefore could perform a similar anti-apoptotic function in neutrophils and eosinophils. While in our hands TNF-alpha does not produce significant cytotoxic effects in eosinophils, co-treatment with gliotoxin caused these cells to become highly responsive to this cytokine producing greatly increased levels of apoptosis. This suggests that both of these inflammatory cell types could be stimulated to undergo apoptosis and hence be cleared rapidly by phagocytes at sites of inflammation if activation of the inducible NF-kappa B isoform were inhibited.

The mechanism whereby inactivation of NF-kappa B induces granulocyte apoptosis and increases the cytotoxic response to TNF-alpha is currently unclear. Since gliotoxin and TNF-alpha driven apoptosis are both inhibited by the caspase-inhibitor zVAD-fmk, this, together with the synergy for apoptosis observed with these agents, implies that NF-kappa B or an NF-kappa B regulated step influences granulocyte apoptosis at an intermediate step between the TNF-alpha receptor and caspase activation. The possibility that NF-kappa B controls the transcriptional activity of a gene(s) which induces the synthesis of survival proteins is supported by the observation that cycloheximide also increases apoptosis in granulocytes (49). This suggests a strong link between inducible NF-kappa B activation and the control of TNF-alpha -induced apoptosis, possibly via the production of a protein inhibitor of this pathway. Indeed, as we have shown, protein synthesis inhibition enhances the pro-apoptotic effect of TNF-alpha as early as 2 h of culture. Indeed, one possible candidate for this protein has already been suggested: A20, a protein induced by TNF-alpha activation of NF-kappa B (56, 57), has been shown to protect against TNF-alpha induced cell death by acting at the level of the TNF-alpha receptor-associated proteins TRAF-1 and TRAF2 (58). Although A20 has yet to be demonstrated in neutrophils or eosinophils, this would represent an attractive candidate protein to fulfill such a role.

The ability of gliotoxin to enhance the cytotoxic effects of TNF-alpha and itself produce a rapid onset of apoptosis in inflammatory cells such as neutrophils and eosinophils may suggest NF-kappa B inhibition as a logical therapeutic target in the treatment of inflammatory conditions. In a rat model of lung inflammation, suppression of NF-kappa B activity has already been shown to block the development of neutrophil lung inflammation by inhibiting the synthesis of chemotaxins (59). Our results suggest that NF-kappa B inhibition may also be of benefit in enhancing the resolution of inflammation by allowing a more rapid clearance of granulocytes. We therefore propose that granulocyte apoptosis is regulated by an inducible form of the transcription factor NF-kappa B and suggest that inhibition of this transcription factor may be exploited for therapeutic benefit in inflammatory conditions where granulocytes play a prominent role.

    FOOTNOTES

* This work was supported in part by Medical Research Council Program Grant G9016491 and the Wellcome Trust.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Supported by a Glaxo-Wellcome studentship.

§ Wellcome Senior Research Fellow in Clinical Science.

parallel To whom correspondence should be addressed: Respiratory Medicine Unit, Dept. of Medicine, Rayne Laboratory, University of Edinburgh Medical School, Teviot Place, Edinburgh, EH8 9AG, Scotland, United Kingdom. Tel.: 44-131-651-1323; Fax: 44-131-650-4384; E-mail: a.g.rossi{at}ed.ac.uk.

The abbreviations used are: TNF-alpha , tumor necrosis factor-alpha ; EMSA, electrophoretic mobility shift assay; LPS, lipopolysaccharide; NF-kappa B, nuclear factor-kappa B; PDTC, pyrrolidine dithiocarbamate; zVAD-fmk, benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone: DMEM, Dulbecco's modified Eagle's medium.
    REFERENCES
Top
Abstract
Introduction
References

  1. Savill, J. S., Wyllie, A. H., Henson, J. E., Walport, M. J., Henson, P. M., and Haslett, C. (1989) J. Clin. Invest. 83, 865-875[Medline] [Order article via Infotrieve]
  2. Stern, M., Meagher, L., Savill, J., and Haslett, C. (1992) J. Immunol. 148, 3543-3549[Abstract/Free Full Text]
  3. Whyte, M. K. B., Meagher, L. C., MacDermot, J., and Haslett, C. (1993) J. Immunol. 150, 5124-5134[Abstract/Free Full Text]
  4. Stern, M., Savill, J. S., and Haslett, C. (1996) Am. J. Pathol. 149, 911-921[Abstract]
  5. Her, E., Frazer, J., Austen, F., and Owen, W. F., Jr. (1991) J. Clin. Invest. 88, 1982-1987[Medline] [Order article via Infotrieve]
  6. Colotta, F., Re, F., Polentarutti, N., Sozzani, S., and Mantovani, A. (1992) Blood 80, 2012-2020[Abstract]
  7. Lee, A., Whyte, M. K. B., and Haslett, C. (1993) J. Leukocyte Biol. 54, 283-288[Abstract]
  8. Takanaski, S., Nonaka, R, Xing, X., O'Byrne, P., Dolovich, J., and Jordanna, M. (1994) J. Exp. Med. 180, 711-715[Abstract]
  9. Meagher, L. C., Cousin, J. M., Seckl, J. R., and Haslett, C. (1996) J. Immunol. 156, 4422-4428[Abstract]
  10. Murray, J., Barbara, J. A. J., Dunkley, S. A., Lopez, A. F., Van Ostade, X., Condliffe, A. M., Dransfield, I., Haslett, C., and Chilvers, E. R. (1997) Blood 90, 2772-2783[Abstract/Free Full Text]
  11. Henkel, T., Machleidt, T., Alkalay, I., Kronke, M., Ben-Neriah, Y., and Baeuerle, P. A. (1993) Nature 365, 182-185[CrossRef][Medline] [Order article via Infotrieve]
  12. Traenckner, E. B., Wilk, S., and Baeuerle, P. A. (1994) EMBO J. 13, 5433-5441[Abstract]
  13. Finco, T. S., Beg, A. A., and Baldwin, A. S., Jr. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 11884-11888[Abstract/Free Full Text]
  14. Baeuerle, P. A., and Baichwal, V. R. (1994) Adv. Immunol. 62, 1192-1198
  15. May, M. J., and Ghosh, S. (1998) Immunol. Today 19, 80-88[CrossRef][Medline] [Order article via Infotrieve]
  16. Baldwin, A., Jr. (1996) Annu. Rev. Immunol. 14, 649-681[CrossRef][Medline] [Order article via Infotrieve]
  17. Wu, M., Lee, H., Bellas, R. E., Schauer, S. L., Arsura, M., Katz, D., FitzGerald, M. J., Rothstein, T. L., Sherr, D. H., and Sonenshein, G. E. (1996) EMBO J. 15, 4682-4690[Abstract]
  18. Grimm, S., Bauer, M. K. A., Baeuerle, P. A., and Schulze-Osthoff, K. (1996) J. Cell Biol. 134, 13-23[Abstract]
  19. Beg, A. A., and Baltimore, D. (1996) Science 274, 782-784[Abstract/Free Full Text]
  20. Van Antwerp, D. J., Martin, S. J., Kafri, T., Green, D. R., and Verma, I. M. (1996) Science 274, 787-789[Abstract/Free Full Text]
  21. Wang, C., Mayo, M. W., and Baldwin, A. S. (1996) Science 274, 784-787[Abstract/Free Full Text]
  22. McDonald, P. P., Bald, A., and Cassatella, A. A. (1997) Blood 89, 3421-3433[Abstract/Free Full Text]
  23. Browning, D. D., Pan, Z. K., Prossnitz, E. R., and Ye, R. D. (1997) J. Biol. Chem. 272, 7995-8001[Abstract/Free Full Text]
  24. Braithwaite, A. W., Eichner, R. D., Waring, P., and Müllbacher, A. (1987) Mol. Immunol. 24, 47-55[CrossRef][Medline] [Order article via Infotrieve]
  25. Ozaki, K., Takeda, H., Iwahashi, H., Kitano, S., and Hanazawa, S. (1997) FEBS Lett. 410, 297-300[CrossRef][Medline] [Order article via Infotrieve]
  26. Waring, P., Eichner, R. D., Müllbacher, A., and Sjaarda, A. (1988) J. Biol. Chem. 263, 18493-18499[Abstract/Free Full Text]
  27. Sutton, P., Newcombe, N. R., Waring, P., and Müllbacher, A. (1994) Infect. Immunol. 62, 1192-1198[Abstract]
  28. Pahl, H. L., Krauß, B., Schulze-Osthoff, K., Decker, T., Traenckner, E. B., Vogt, M., Myers, C., Parks, T., Warring, P., Mühlbacher, A., Czernilofsky, A-P., and Baeuerle, P. A. (1996) J. Exp. Med. 183, 1829-1840[Abstract]
  29. Haslett, C., Guthrie, L. A., Kopaniak, M. M., Johnston, R. B., Jr., and Henson, P. M. (1985) Am. J. Pathol. 119, 101-110[Abstract]
  30. Dignam, J. D., Lebovitz, R. M., and Roeder, R. G. (1983) Nucleic Acids Res. 11, 1475-1489[Abstract]
  31. Whyte, M. K., Hardwick, S. J., Meagher, L. C., Savill, J. S., and Haslett, C. (1993) J. Clin. Invest. 92, 446-455[Medline] [Order article via Infotrieve]
  32. Cousin, J. M., Haslett, C., and Rossi, A. G. (1997) Biochem. Soc. Trans. 25, 243S[Medline] [Order article via Infotrieve]
  33. Rossi, A. G., Cousin, J. M., Dransfield, I., Lawson, M. F., Chilvers, E. R., and Haslett, C. (1995) Biochem. Biophys. Res. Commun. 271, 892-899
  34. Hannah, S., Mecklenburgh, K., Rahman, I., Bellingan, G. J., Greening, A., Haslett, C., and Chilvers, E. R. (1995) FEBS Lett. 372, 233-237[CrossRef][Medline] [Order article via Infotrieve]
  35. Hachiya, O., Takeda, Y., Miyata, H., Watanabe, H., Yamashita, T., and Sendo, F. (1995) Microbiol. Immunol. 39, 715-723[Medline] [Order article via Infotrieve]
  36. Ward, C., Murray, J., Bruce, L., Farrow, S., Chilvers, E. R., Hannah, S., Haslett, C., and Rossi, A. G. (1997) Biochem. Soc. Trans. 25, 245S[Medline] [Order article via Infotrieve]
  37. Lin, Y., Yao, S., Veach, R. A., Torgerson, T. R., and Hawiger, J. (1995) J. Biol. Chem. 270, 14255-14258[Abstract/Free Full Text]
  38. Adams, J., and Stein, R. (1996) Annu. Rep. Med. Chem. 31, 279-287
  39. Singh, S., and Aggarwal, B. B. (1995) J. Biol Chem. 270, 24995-25000[Abstract/Free Full Text]
  40. Schreck, R., Meier, B., Mannel, D. N., Droge, W., and Baeuerle, P. A. (1992) J. Exp. Med. 175, 1181-1194[Abstract]
  41. Druker, B. J., Neumann, M., Okuda, K., Franza, B. R, and Griffin, J. D. (1994) J. Biol. Chem. 269, 5387-5390[Abstract/Free Full Text]
  42. MacDonald, P. P., and Cassatella, M. A. (1997) FEBS Lett. 412, 583-586[CrossRef][Medline] [Order article via Infotrieve]
  43. Vollebregt, M., Hampton, M. B., and Winterbourn, C. C. (1998) FEBS Lett. 432, 40-44[CrossRef][Medline] [Order article via Infotrieve]
  44. Lui, Z., Hsu, H., Goeddel, D. V., and Karin, M. (1996) Cell 87, 565-576[Medline] [Order article via Infotrieve]
  45. Sutton, P., Beaver, J., and Waring, P. (1995) Biochem. Pharmacol. 50, 2009-2014[CrossRef][Medline] [Order article via Infotrieve]
  46. Hallsworth, M. P., Giembycz, M. A., Barnes, P. J., and Lee, T. H. (1996) Br. J. Pharmacol. 117, 79-86[Abstract]
  47. Waring, P., Khan, T., and Sjaarda, A. (1997) J. Biol. Chem. 272, 17929-17936[Abstract/Free Full Text]
  48. Waring, P. (1990) J. Biol. Chem. 265, 14476-14480[Abstract/Free Full Text]
  49. Whyte, M. K. B., Savill, J., Meagher, L. C., Lee, A., and Haslett, C. (1997) J. Leukocyte Biol. 62, 195-202[Abstract]
  50. Newton, R., Adcock, I. M., and Barnes, P. J. (1996) Biochem. Biophy. Res. Commun. 218, 518-523[CrossRef][Medline] [Order article via Infotrieve]
  51. Faggioli, L., Costanzo, C., Merola, M., Furia, A., and Palmieri, M. (1997) Biochem. Biophy. Res. Commun. 233, 507-513[CrossRef][Medline] [Order article via Infotrieve]
  52. Matthews, J. R., Botting, C. H., Panico, M., Morris, H. R., and Hay, R. T. (1997) Nucleic Acids Res. 24, 2236-2242[Abstract/Free Full Text]
  53. Peng, H., Libby, P., and Liao, J. K. (1995) J. Biol. Chem. 270, 14214-14219[Abstract/Free Full Text]
  54. Wong, T., Rossi, A. G., and Chilvers, E. R. (1997) J. Clin. Sci. 92, 7
  55. Beg, A. A., Sha, W. C., Bronson, R. T., Ghosh, S., and Baltimore, D. (1995) Nature 376, 167-170[CrossRef][Medline] [Order article via Infotrieve]
  56. Krikos, A., Laherty, C. D., and Dixit, V. M. (1992) J. Biol. Chem. 267, 17971-17976[Abstract/Free Full Text]
  57. Opipari, A. W., Hu, H. M., Yabkowitz, R., and Dixit, V. M. (1992) J. Biol. Chem. 267, 12424-12427[Abstract/Free Full Text]
  58. Song, H. Y., Rothe, M., and Goeddel, D. V. (1996) Biochemistry 93, 6721-6725
  59. Blackwell, T. S., Blackwell, T., Holden, E. P., Christman, B. W., and Christman, J. W. (1996) J. Immunol. 157, 1630-1673[Abstract]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.